Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.28

+5.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mao II who wrote (13359)	10/6/2004 5:20:46 PM
From: Icebrg	Read Replies (1) of 52153

M2 >>Why do you doubt a substantial run-up? Stellar 3 is completely blinded and date for unblinding has been substantially extended due to longer-lived patients.>> I would like to quote my past encounters with the un-anticipated as a reason for my doubt. One possible explanation for the extended timeline might be differences in the study population. PS - the Performance Status which has been used as a recruitment criterium seems to be a rather rough way of characterising the physical condition of a cancer patient. I guess it is for example possible that differences in inclusion/exclusion criteria compared to historical studies may account for an extended survival. The Stellar studies are by the way not completely blinded. At the site level they are actually open label due to the fact that paclitaxel requires a three hours infusion and Xyotax can be given over 10 minutes. For Xyotax no pre-tretments are required etc. etc. Each patient and each investigator will have full knowledge of which of the treatment arms they belong to. It is only on the aggregated level that a blind is supposed to exist. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next